Pricing

Syros Pharmaceuticals Inc. (SYRS)

followers ยท
Sector: HEALTH CARE
Industry: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Nancy A. Simonian
Employees: 120
Web site: syros.com
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140
617-744-1340
Stock Split History
Date Ratio
2022-09-19 1:10
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Syros Pharmaceuticals, Inc. focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available